BNTX • NASDAQ
BioNTech SE - ADR
$134.04
After Hours:
$133.98
(0.045%)-0.060
Closed: Jun 24, 7:59:52 PM GMT-4 · USD · NASDAQ · Disclaimer
StockUS listed securityDE headquartered
Previous close
$132.29
Day range
$129.22 - $134.29
Year range
$117.08 - $464.00
Market cap
32.57B USD
Avg Volume
1.23M
P/E ratio
2.49
Dividend yield
-
Primary exchange
NASDAQ
Financials
Income Statement
Financial performance
Revenue
Net income
(EUR)Mar 2022Y/Y change
Revenue
6.37B211.20%
Operating expense
451.80M133.13%
Net income
3.70B227.88%
Earnings per share
14.24224.37%
EBITDA
4.66B184.88%
Effective tax rate
26.29%
Financial performance
Total assets
Total liabilities
(EUR)Mar 2022Y/Y change
Cash and short-term investments
6.16B591.14%
Total assets
20.30B382.78%
Total liabilities
4.39B160.45%
Total equity
15.91B
Shares outstanding
243.01M
Price to book
2.02
Return on assets
64.06%
Return on capital
81.80%
Financial performance
Net change in cash
(EUR)Mar 2022Y/Y change
Net income
3.70B227.88%
Cash from operations
4.05B1,401.06%
Cash from investing
287.40M1,115.55%
Cash from financing
80.30M1,884.44%
Net change in cash
4.47B1,503.01%
Free cash flow
3.04B594.38%
About
BioNTech SE is a German biotechnology company based in Mainz that develops and manufactures active immunotherapies for patient-specific approaches to the treatment of diseases. It develops pharmaceutical candidates based on messenger ribonucleic acid for use as individualized cancer immunotherapies, as vaccines against infectious diseases and as protein replacement therapies for rare diseases, and also engineered cell therapy, novel antibodies and small molecule immunomodulators as treatment options for cancer. The company has developed an mRNA-based human therapeutic for intravenous administration to bring individualized mRNA-based cancer immunotherapy to clinical trials and to establish its own manufacturing process. In 2020, BioNTech, partnering with Pfizer for testing and logistics, developed the RNA vaccine BNT162b2 for preventing COVID-19 infections, which at the time offered a 91% efficacy in preventing confirmed COVID-19 occurring at least 7 days after the second dose of vaccine. On 2 December 2020, temporary HMR authorization was granted by the United Kingdom government for BNT162b2 vaccinations within the United Kingdom. It was the first mRNA vaccine ever authorized. Wikipedia
Founded
2008
Headquarters
Employees
3,082
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
People also search for